Yaxin Medical

MGI Tech: Lead Life Science Through Intelligent Innovation

In the dynamic realm of bioscience, MGI Tech Co., Ltd. (MGI) has emerged as a torchbearer, captivating attention with its trailblazing achievements and relentless dedication to innovation.

20 Chinese Companies to Watch in Q1 2023– Healthcare+

Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China’s healthcare space in Q1 2023. The following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, the activity level and the segments in which the startups operate.

Tsingke Biotechnology: More Opportunities in the International Market of Gene Synthesis

‘Globalization is the only way to the development of the industry. It is more conducive to the rapid progress of the industry for domestic enterprises to compete with well-known overseas enterprises.’

Opportunities and Challenges Hidden in the CGT Industry in China

CGT (Cell and Gene Therapy) is a sector with high growth potential. CAR-T, as one of the main CGT currently, presents great value for both doctors and patients. This article showcases the industry pain points and opportunities faced in the CAR-T sub-sector.

China VC Investment List Q4 2022 – Healthcare

For healthcare, we at EqualOcean have identified 20 companies worth watching in Q4 identified by proceedings. We select venture capital investments of over CNY 200 million on average or the equivalent value in USD in a single round.

15 Companies to Watch in December 2022 — Healthcare

Editor's note: We at EqualOcean tracked the major funding rounds and industry events that took place in China's healthcare space in December 2022. And the following is a list of deals that we have selected for you, based on a number of criteria, including the funding amount, the financial backers, and the segments in which the companies operate.

2022 China Year-in-Review | Healthcare

2022 has been a tough year for most of the pharmaceutical companies but cold winter will pass eventually. We at EqualOcean presented the 2022 year-in-review in two parts. In the second part, we will list major M&A, product approvals, and strategic collaboration news. It's by no means exhaustive, but it'll shed some light on what's to come

2022 China Year-in-Review | Healthcare

2022 has been a tough year for most of the pharmaceutical companies but cold winter will pass eventually. We at EqualOcean presented the 2022 year-in-review in two parts. In the first part, we will list major financing and IPO news. It's by no means exhaustive, but it'll shed some light on what's to come.

Challenges and Opportunities Possessed by Digital Therapeutics Industry

Following the digital therapeutics series report, this article is centered on the challenges and opportunities faced by the digital therapeutics industry and aims to provide insights on the two above aspects.

EqualOcean 2022 China AI Health 30 Companies list Reveals

Starting from September 2022, EqualOcean had been conducting deep market research and expert interviews aiming to select out 30 most representative China-based companies in the AI Health sector that are with the most growth and development potential. It is finally officially finalized, and we give our deep and sincere congratulations to those 30 companies and wish them all the best in the future.

Dissection of Applications of AI in China’s Healthcare Industry

As AI enables automatic problem-solving and is highly intelligence, it can be applied to a wide variety of fields in the healthcare, especially for the labour intensive tasks. In China, from the basic medical health records to the complex disease treatment planning and prediction, you can always find the involvement of AI. Here, we choose seven sectors with more mature development and introduced them.

China VC Investment List Q3 2022 – Healthcare

This is part of a seven-part series on China's VC investment in Q3 2022. This series features firms spanning seven industries, including automaking, healthcare, new consumption, intelligent hardware, smart manufacturing, enterprise services and emerging technologies.

15 Companies to Watch in August 2022- Healthcare

Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China’s healthcare space in August 2022. And the following is a list of deals that we have selected for you, based on a number of criteria including the funding amount, the financial backers, and the segments in which the startups operate.

2022 Informatization of China's Rehabilitation Industry

The rehabilitation industry caught the attention of the Chinese government again in 2021, and the industry entered a phase of accelerated development. The rehabilitation industry will first supplement medical resources and continue to explore a rehabilitation model that suits China's actual conditions. Under this context, EqualOcean Intelligence, together with Neusoft Group, released the 2022 Research Report On the Informatization of China's Rehabilitation Industry.

Analysis of In Vitro Diagnostics Industry in China

It has been almost three years since the coronavirus outbreak. In the post-Covid era, PCR tests and antigen reagents have become part of daily essentials. The increasing demand for PCR tests drives the development of IVD in China. What is IVD? How to explain its popularity in China over the past two or three years? You will find all the answers above in this article.

What Waits Ahead for China’s Healthcare Innovation and its Globalization?

China has been of great interest to global healthcare investors and organizations. This month, we featured four guest speakers from different industry groups under heathcare to share their thoughts on China’s healthcare innovation and globalization.

15 Companies to Watch in July 2022 - Healthcare

Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China's healthcare space in July 2022. And the following is a list of deals that we have selected for you, based on a number of criteria including the funding amount, the financial backers, and the segments in which the startups operate.

China's First Oral COVID-19 Antiviral Medicine in Dispute

An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.

WIM 2022: Transcript of Fireside Chat of Biotech [1/2]

EqualOcean organized the WIM2022 event in New York City from July 29 to July 30, 2022. The following is the transcript for Fireside Chat of Biotech. Leon Tang, Bing Yuan, Ying Huang, Dahai Guo, and Sally Wang are the five guest speakers in this chat.

WIM 2022: Transcript of Fireside Chat of Biotech [2/2]

EqualOcean organized the WIM2022 event in New York City from July 29 to July 30, 2022. The following is the transcript for Fireside Chat of Biotech. Leon Tang, Bing Yuan, Ying Huang, Dahai Guo, and Sally Wang are the five guest speakers in this chat.